Evidence map›Paper›PMID 39195229›Full record

ArticleCells2024

Enhancing Maturation and Translatability of Human Pluripotent Stem Cell-Derived Cardiomyocytes through a Novel Medium Containing Acetyl-CoA Carboxylase 2 Inhibitor.

Cláudia Correia, Jonas Christoffersson, Sandra Tejedor, Saïd El-Haou, Meztli Matadamas-Guzman, Syam Nair, Pierre Dönnes, Gentian Musa, Mattias Rohman, Monika Sundqvist and 9 more

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. EV-Encapsulated Mitochondrial miRNAs: Enhancing Cardiomyocyte Bioenergetics.International journal of molecular sciences · 2026
    Review
  3. Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Cláudia CorreiaResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Jonas ChristofferssonResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0001-5914-2837
Sandra TejedorResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0001-5945-817X
Saïd El-HaouMechanistic Biology and Profiling, Discovery Sciences, AstraZeneca R&D, Cambridge CB2 0AA, UK.
Meztli Matadamas-GuzmanResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0001-7126-6875
Syam NairResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Pierre DönnesSystems Biology Research Center, School of Bioscience, University of Skövde, 54128 Skövde, Sweden.ORCID 0000-0002-4613-2952
Gentian MusaResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Mattias RohmanDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Monika SundqvistResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Rebecca B RiddleResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0002-1670-9589
Bramasta NugrahaResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0002-0799-1594
Ioritz Sorzabal BellidoData Sciences and Quantitative Biology, Discovery Sciences, AstraZeneca R&D, Cambridge CB2 0AA, UK.
Markus JohanssonSystems Biology Research Center, School of Bioscience, University of Skövde, 54128 Skövde, Sweden.ORCID 0000-0002-5134-4749
Qing-Dong WangResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0001-9570-4411
Alejandro HidalgoResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.
Karin JennbackenResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0003-1254-5158
Jane SynnergrenSystems Biology Research Center, School of Bioscience, University of Skövde, 54128 Skövde, Sweden.
Daniela SpäterResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 43150 Gothenburg, Sweden.ORCID 0000-0002-5398-1784

Funding

Swedish Knowledge Foundation 20200014
6 · The paper itself

Abstract

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) constitute an appealing tool for drug discovery, disease modeling, and cardiotoxicity screening. However, their physiological immaturity, resembling CMs in the late fetal stage, limits their utility. Herein, we have developed a novel, scalable cell culture medium designed to enhance the maturation of hPSC-CMs. This medium facilitates a metabolic shift towards fatty acid utilization and augments mitochondrial function by targeting Acetyl-CoA carboxylase 2 (ACC2) with a specific small molecule inhibitor. Our findings demonstrate that this maturation protocol significantly advances the metabolic, structural, molecular and functional maturity of hPSC-CMs at various stages of differentiation. Furthermore, it enables the creation of cardiac microtissues with superior structural integrity and contractile properties. Notably, hPSC-CMs cultured in this optimized maturation medium display increased accuracy in modeling a hypertrophic cardiac phenotype following acute endothelin-1 induction and show a strong correlation between in vitro and in vivo target engagement in drug screening efforts. This approach holds promise for improving the utility and translatability of hPSC-CMs in cardiac disease modeling and drug discovery.

Indexed as

Acetyl-CoA CarboxylaseCell DifferentiationMyocytes, CardiacPluripotent Stem CellsAnimalsCulture MediaEnzyme InhibitorsHumansACACB protein, humanAcetyl-CoA CarboxylaseCulture MediaEnzyme Inhibitorsacetyl-CoA carboxylase 2 (ACC2)cardiac hypertrophyhuman pluripotent stem cell-derived cardiomyocyte (hPSC-CM) maturationin vitro-to-in vivo correlationtranslatable in vitro model

Identifiers

PMID39195229
PMCPMC11352932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.